nhe3

EIPA (L593754) is a TRPP3 channel inhibitor (IC50=10.5 μM) and an inhibitor of Na+ H+ exchange (NHE). EIPA inhibits megacytosis, promotes autophagy, and can be used in inflammation and tumor studies.

NHE3-IN-1 is a inhibitor of Na+/H+-exchanger 3 (NHE-3).

NHE3-IN-2 is an inhibitor of Na + H + exchanger-3 (NHE3)[1].

NHE3-IN-3 (Compound 1) is a potent inhibitor of isoform 3 of the Na+ H+ exchanger (NHE3), exhibiting pIC50 values of 6.2 and 6.6 against human and rat NHE3, respectively, and demonstrates exceptional oral bioavailability of 98% in Sprague–Dawley rats [1].

S3226 is an inhibitor of Na+ H+ exchanger 3 (NHE3), with an IC50 of 0.2 µmol L in rat fibroblasts transfected with NHE3. It exhibits protective effects in a rat model of ischemic acute renal failure.

Tenapanor (RDX 5791) is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3, which plays a prominent role in sodium handling in the gastrointestinal tract and kidney. Tenapanor possesses an excellent preclinical safety profile and, as of now, there are no serious concerns about its side effects.

Tenapanor( AZD-1722, RDX 5791) is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3, which is used for sodium handling in the gastrointestinal tract and kidney.